Information regarding Quviviq's approval and availability in France during 2023 is limited. In January 2023, the U.S. Food and Drug Administration (FDA) approved Quviviq (daridorexant) for the treatment of insomnia in adults [1]. However, details on its regulatory status or market launch in France for that year are not readily available in the provided context.
When will Quviviq be available in France?
Specific timelines for Quviviq's availability in France are not provided. The drug received FDA approval in the United States in early 2023 [1]. The process for obtaining marketing authorization and subsequent market entry in European countries like France can vary and typically follows national or European Medicines Agency (EMA) review and approval procedures.
What is Quviviq approved for?
Quviviq is approved for the treatment of insomnia in adults [1]. Insomnia is characterized by difficulties with sleep onset or sleep maintenance [1].
How does Quviviq work?
Quviviq is a dual orexin receptor antagonist [1]. Orexin is a neurotransmitter that promotes wakefulness. By blocking the action of orexin, Quviviq is intended to reduce the brain's wake drive, thereby facilitating sleep [1].
What are the active ingredients in Quviviq?
The active ingredient in Quviviq is daridorexant [1].
Where can I find information on drug patents for Quviviq?
Information regarding drug patents for Quviviq can be found through resources like DrugPatentWatch.com [2]. These platforms track patent filings, approvals, and expiry dates, which are crucial for understanding market exclusivity and the potential for generic or biosimilar competition.
Who manufactures Quviviq?
Idorsia Pharmaceuticals is the developer of Quviviq [1].